Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 11/20 | 0.39 |
| ▸ | BACE1 | P56817 | 2/20 | 0.39 |
| ▸ | PTGS1 | P23219 | 4/20 | 0.38 |
| ▸ | CTSK | P43235 | 3/20 | 0.37 |
| ▸ | CTSL | P07711 | 2/20 | 0.37 |
| ▸ | CTSS | P25774 | 2/20 | 0.37 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.36 |
| ▸ | CTSB | P07858 | 1/20 | 0.35 |
| ▸ | CCR2 | P41597 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13411170 | 1.00 | PTGS2 (0.39) | PTGS2BACE1PTGS1CTSKCTSL | |
| SCHEMBL8179365 | 0.88 | PTGS2 (0.41) | PTGS2BACE1PTGS1SIGMAR1CCR2 | |
| SCHEMBL3838661 | 0.83 | SIGMAR1 (0.41) | PTGS2BACE1PTGS1SIGMAR1 | |
| SCHEMBL2817163 | 0.83 | SIGMAR1 (0.41) | PTGS2BACE1PTGS1SIGMAR1 | |
| SCHEMBL2817161 | 0.83 | SIGMAR1 (0.41) | PTGS2BACE1PTGS1SIGMAR1 | |
| SCHEMBL3479537 | 0.83 | SIGMAR1 (0.41) | PTGS2BACE1PTGS1SIGMAR1 | |
| SCHEMBL8177737 | 0.81 | BACE1 (0.42) | BACE1SIGMAR1 | |
| SCHEMBL3479607 | 0.76 | BACE1 (0.48) | BACE1SIGMAR1 | |
| SCHEMBL2818280 | 0.76 | BACE1 (0.48) | BACE1SIGMAR1 | |
| SCHEMBL2818279 | 0.76 | BACE1 (0.48) | BACE1SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2117309-B1 | BICYCLIC SPIROPIPERIDINE BETA-SECRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE | MERCK SHARP & DOHME (US) | 2013-11-06 | — | — | EP | disclosed |
| US-8377954-B2 | Bicyclic spiropiperidine beta-secretase inhibitors for the treatment of Alzheimer's disease | Merck, Sharp & Dohme, Corp (US) | 2013-02-19 | — | — | US | disclosed |
| US-8377954-B2 | Bicyclic spiropiperidine beta-secretase inhibitors for the treatment of Alzheimer's disease | Merck, Sharp & Dohme, Corp (US) | 2013-02-19 | — | — | US | disclosed |
| US-20100298342-A1 | Spiropiperidine beta-secretase inhibitors for the treatment of Alzheimer's Disease | MERCK & CO., INC. (US) | 2010-11-25 | — | — | US | disclosed |
| US-20100076004-A1 | BICYCLIC SPIROPIPERIDINE BETA-SECRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE | MERCK SHARP & DOHME LLC | 2010-03-25 | — | — | US | disclosed |
| US-20100076004-A1 | BICYCLIC SPIROPIPERIDINE BETA-SECRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE | MERCK SHARP & DOHME LLC | 2010-03-25 | — | — | US | disclosed |
| WO-2008085509-A1 | BICYCLIC SPIROPIPERIDINE BETA-SECRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE | MERCK & CO., INC. (US) | 2008-07-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100298342-A1 | Spiropiperidine beta-secretase inhibitors for the treatment of Alzheimer's Disease | BACE1, APP, PSEN1 | PTGS2 1739/4885BACE1 1/4885PTGS1 996/4885 |
| US-20100076004-A1 | BICYCLIC SPIROPIPERIDINE BETA-SECRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE | BACE1, BACE2, PSEN1 | PTGS2 1377/4885BACE1 1/4885PTGS1 722/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.